Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

vTv Therapeutics Crashes on Alzheimer's Drug Study Failure

vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.

    Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy

    Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.

      Biogen Cracks the Case With AbbVie for Humira Biosimilar

      Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.

        Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

        Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study

          Pfizer's Lung Cancer Candidate Gets FDA's Priority Review

          Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.

            Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale

            Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.

              The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife

              The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife

                The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources

                The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources

                  Mark Vickery headshot

                  Top Research Reports for Facebook, UnitedHealth & Pfizer

                  Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), UnitedHealth (UNH) and Pfizer (PFE).

                    Alnylam Falls on Pfizer's Rare Disease Drug Success

                    Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.

                      Shire's Stock Continues to Rise as Takeda Sets Eyes On it

                      Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.

                        Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease

                        Amgen's (AMGN) leukemia drug, Blincyto is the first approved drug for the treatment of minimal residual disease in the United States.

                          Pfizer's Rare Disease Candidate Meets Endpoint in Phase III

                          Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.

                            Tirthankar Chakraborty headshot

                            5 Juicy Dividend Stocks to Ride Out a Dicey April

                            April is historically the second best month of the year, but there are ample reasons why it could be cruel this year.

                              Tackle Market Uncertainty With These 3 Quality Dividend ETFs

                              Consider these three dividend ETFs for your portfolio to fight growing market uncertainty.

                                Indrajit Bandyopadhyay headshot

                                Is a Recession in the Cards? 4 Safe Bets for Your Portfolio

                                After nearly a decade of the global financial crisis of 2007-2008, some analysts believe that the threat of another recession lurks. However, the time and its impact is yet to be ascertained.

                                  Merck KGaA's Tepotinib Gets Fast Track Designation in Japan

                                  Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.

                                    Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV

                                    Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.

                                      Kinjel Shah headshot

                                      4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End

                                      The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying

                                        Pfizer's Chantix Fails in Phase IV Study in Young Smokers

                                        Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.

                                          Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod

                                          Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.

                                            Tirthankar Chakraborty headshot

                                            Wall Street Braces for Ugliest March: 5 Ultra-Safe Picks

                                            The Dow is on track for its worst March in nearly 40 years, while the month is likely to be most awful for the S&P 500 and the Nasdaq since 2001.

                                              Novartis Gets Positive CHMP Opinion on Biosimilar Remicade

                                              The CHMP gave a positive opinion to Novartis (NVS) proposed biosimilar of Remicade for all of the branded drug's indications. A decision from the EMA is expected shortly.

                                                The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

                                                The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

                                                  Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus

                                                  Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.